2151854-33-8

MPT0G211 mesylate is a powerful and selective HDAC6 inhibitor (IC50 = 0.291 nM), with high oral bioavailability. It exhibits remarkable selectivity for HDAC6 over other HDAC isoforms (>1000-fold selectivity). Additionally, MPT0G211 mesylate can effectively cross the blood-brain barrier. In preclinical studies using an Alzheimer's disease model, MPT0G211 mesylate has shown promising results in reducing tau phosphorylation and cognitive deficits. Furthermore, this compound exhibits anti-metastatic and neuroprotective effects, making it a potential candidate for anticancer interventions. [1] [2] [3].

MPT0G211 是一种具有高效性选择性和口服活性的 HDAC6 抑制剂 (IC50=0.291 nM)，具有神经保护作用在人乳腺癌细胞中显示出有抗转移活性。MPT0G211 对 HDAC6 的亲和力是其他 HDAC 亚型的 1000 倍。MPT0G211 可以透过血脑屏障，可用于改善阿尔茨海默病模型中 tau 磷酸化和认知缺陷。